204 related articles for article (PubMed ID: 18552823)
1. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
[TBL] [Abstract][Full Text] [Related]
2. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
3. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of HMB45 and negative PRAME expression in halo nevi.
Ruby KN; Li Z; Yan S
J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871
[TBL] [Abstract][Full Text] [Related]
5. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
6. Malignant melanoma with paradoxical maturation.
Ruhoy SM; Prieto VG; Eliason SL; Grichnik JM; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Dec; 24(12):1600-14. PubMed ID: 11117780
[TBL] [Abstract][Full Text] [Related]
7. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors.
Garola R; Singh V
Pathol Res Pract; 2019 Oct; 215(10):152550. PubMed ID: 31351802
[TBL] [Abstract][Full Text] [Related]
8. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of benign and malignant melanocytic lesions of the conjunctiva using double-staining.
Soon AK; Brownstein S; Tang T; Saleh S; Jiang K; Levac J; Blanco P; Farmer J
Can J Ophthalmol; 2019 Dec; 54(6):699-707. PubMed ID: 31836103
[TBL] [Abstract][Full Text] [Related]
10. Proliferative activity of primary cutaneous melanocytic tumours.
Kuwata T; Kitagawa M; Kasuga T
Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions.
Nielsen PS; Riber-Hansen R; Steiniche T
Am J Dermatopathol; 2011 Jun; 33(4):361-70. PubMed ID: 21610457
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy.
Wagner SN; Wagner C; Schultewolter T; Goos M
Cancer Immunol Immunother; 1997 Jun; 44(4):239-47. PubMed ID: 9222283
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
15. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA.
Sundram U; Harvell JD; Rouse RV; Natkunam Y
Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225
[TBL] [Abstract][Full Text] [Related]
16. The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas.
Uguen A; Uguen M; Guibourg B; Talagas M; Marcorelles P; De Braekeleer M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):361-367. PubMed ID: 27490764
[TBL] [Abstract][Full Text] [Related]
17. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
18. Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.
Milman T; Zhang Q; Ang S; Elder D; Ida CM; Salomao DR; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC
Hum Pathol; 2020 Sep; 103():107-119. PubMed ID: 32707054
[TBL] [Abstract][Full Text] [Related]
19. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
20. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]